NCT01472081

Brief Summary

The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
194

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Feb 2012

Longer than P75 for phase_1

Geographic Reach
2 countries

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 26, 2011

Completed
21 days until next milestone

First Posted

Study publicly available on registry

November 16, 2011

Completed
3 months until next milestone

Study Start

First participant enrolled

February 9, 2012

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2016

Completed
3.5 years until next milestone

Results Posted

Study results publicly available

August 2, 2019

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 3, 2021

Completed
Last Updated

December 2, 2021

Status Verified

November 1, 2021

Enrollment Period

4 years

First QC Date

October 26, 2011

Results QC Date

May 23, 2018

Last Update Submit

November 30, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation

    Safety assessments by treatment arm and dose level were based on incidence of AEs, and the incidence of serious adverse events (SAEs). AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.

    From date of first dose to date of last dose plus 100 days (assessed up to March 2016, approximately 49 months)

Secondary Outcomes (5)

  • Best Overall Response Rate (BOR)

    From date of first dose to date of disease progression or subsequent anti-cancer therapy, whichever occurred first (assessed up to March 2016, approximately 49 months)

  • Objective Response Rate (ORR)

    From date of first dose to interim analysis (Assessed up to March 2016, approximately 49 months)

  • Duration of Response (DOR)

    From date of first dose to date of disease progression or death, whichever occurred first (assessed up to March 2016, approximately 49 months)

  • Rate of Progression-free Survival (PFS) at Week 24

    24 weeks

  • Progression-free Survival (PFS)

    From date of first dose to date of disease progression or death, whichever occurred first (assessed up to March 2016, approximately 49 months)

Study Arms (5)

Arm S: Nivolumab + Sunitinib

EXPERIMENTAL

Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons

Biological: NivolumabDrug: Sunitinib

Arm P: Nivolumab + Pazopanib

EXPERIMENTAL

Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons

Biological: NivolumabBiological: Pazopanib

Arm I-1: Nivolumab + Ipilimumab

EXPERIMENTAL

Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons

Biological: NivolumabBiological: Ipilimumab

Arm I-3: Nivolumab + Ipilimumab

EXPERIMENTAL

Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase

Biological: NivolumabBiological: Ipilimumab

Arm IN-3: Nivolumab+Ipilimumab

EXPERIMENTAL

Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase

Biological: NivolumabBiological: Ipilimumab

Interventions

NivolumabBIOLOGICAL
Also known as: BMS-936558 (MDX-1106)
Arm I-1: Nivolumab + IpilimumabArm I-3: Nivolumab + IpilimumabArm IN-3: Nivolumab+IpilimumabArm P: Nivolumab + PazopanibArm S: Nivolumab + Sunitinib
PazopanibBIOLOGICAL
Also known as: Votrient (Pazopanib hydrochloride)
Arm P: Nivolumab + Pazopanib
Also known as: Sutent®, Sunitinib Malate
Arm S: Nivolumab + Sunitinib
IpilimumabBIOLOGICAL
Also known as: YERVOY™
Arm I-1: Nivolumab + IpilimumabArm I-3: Nivolumab + IpilimumabArm IN-3: Nivolumab+Ipilimumab

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with histological confirmation of RCC
  • Advanced or metastatic disease
  • Measurable disease as defined by RECIST 1.1 criteria
  • Karnofsky Performance Status (KPS) ≥80%
  • Available tumor tissue (archival or recent acquisition)
  • Subjects enrolled in the I-1, I-3 expansion arms and IN-3 addition arms must not have received any prior systemic therapy for RCC with the following exceptions:
  • One prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC is allowed provided recurrence occurred ≥ 6 months after the last dose of the adjuvant or neoadjuvant therapy
  • Only prior cytokine based treatment for metastatic RCC \[eg, interferon-alpha (IFN-alpha) or interleukin 2 (IL-2)\] as prior therapy is allowed

You may not qualify if:

  • Active central nervous system (CNS) metastases
  • Active or history of autoimmune disease
  • Ongoing symptomatic cardiac dysrhythmias or uncontrolled atrial fibrillation
  • History of cerebrovascular accident including transient ischemic attack within the past 12 months
  • History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months
  • Chronic systemic steroids (\>10 mg/day Prednisone equivalents) or any other immunosuppressive agents
  • White blood cell (WBC) \<2,000/mm3
  • Neutrophiles \<1,500/mm3
  • Platelets \<100,000/mm3
  • Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x upper limit of normal (ULN)
  • Total Bilirubin \>1.5x ULN (except subjects with Gilbert syndrome, total bilirubin \<3.0 mg/dL)
  • Cardiac ejection fraction \<LLN (lower limit of normal)
  • Serum creatinine \>1.5x ULN or creatinine clearance \<40 mL/min (Cockroft-Gault formula)
  • For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and required permanent discontinuation due to toxicity or required dose reduction or delay during the first 12 weeks of therapy due to toxicity, or received both prior Sunitinib and Pazopanib
  • Poorly controlled hypertension
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

City Of Hope

Duarte, California, 91010-3000, United States

Location

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Baltimore, Maryland, 21287, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

Location

Memorial Sloan Kettering Nassau

New York, New York, 10065, United States

Location

Blumenthal Cancer Center

Charlotte, North Carolina, 28204, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States

Location

University Of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030-4009, United States

Location

Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada

Location

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

BC Cancer Agency - Vancouver Centre

Vancouver, British Columbia, V5Z 4E6, Canada

Location

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 1Z5, Canada

Location

Related Publications (2)

  • Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0.

  • Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2.

Related Links

MeSH Terms

Conditions

Carcinoma, Renal CellClear-cell metastatic renal cell carcinoma

Interventions

NivolumabpazopanibSunitinibIpilimumab

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulinsPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Bristol-Myers Squibb Study Director
Organization
Bristol-Myers Squibb

Study Officials

  • Bristol-Myers Squibb

    Bristol-Myers Squibb

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2011

First Posted

November 16, 2011

Study Start

February 9, 2012

Primary Completion

February 2, 2016

Study Completion

June 3, 2021

Last Updated

December 2, 2021

Results First Posted

August 2, 2019

Record last verified: 2021-11

Locations